Stereotactic Ablative Radio Therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metastatic solid tumours

Combination strategies surely play a crucial role in treatment of cancer. Stereotactic ablative radiotherapy (SABR) has been described to induce abscopal effects particularly in renal cell cancer metastases. This effect is a reaction induced following irradiation of tumour tissue and occurring in an...

Full description

Saved in:
Bibliographic Details
Published in:Journal of translational medicine 2012-05, Vol.10 (1), p.104-104, Article 104
Main Authors: Masucci, Giuseppe V, Wersäll, Peter, Kiessling, Rolf, Lundqvist, Andreas, Lewensohn, Rolf
Format: Article
Language:English
Subjects:
Apoptosis
Biomarkers
Cancer
Cancer therapies
Care and treatment
Chemotherapy
Combined Modality Therapy
Cytokines
Drug dosages
Humans
Immunotherapy
Ionizing radiation
Kidney
Lymphocytes
Metastases
Metastasis
Neoplasm Metastasis
Neoplasms - pathology
Neoplasms - radiotherapy
Neoplasms - therapy
Radiation
Radiation therapy
Radios
Radiotherapy
Radiotherapy - methods
Skin cancer
T cell receptors
Translation
Tumors
Vaccination
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Combination strategies surely play a crucial role in treatment of cancer. Stereotactic ablative radiotherapy (SABR) has been described to induce abscopal effects particularly in renal cell cancer metastases. This effect is a reaction induced following irradiation of tumour tissue and occurring in another metastatic location outside the treatment field. However, this effect is limited and occurs sparsely in about 1-5% of patient. We are planning to improve the clinical outcome of this treatment in metastatic solid tumours by combining SABR with sequential immunotherapeutic treatments including vaccination strategies, adoptive cell therapy, cytokine therapy, or anti-CTLA-4 therapy.
ISSN:1479-5876
1479-5876
DOI:10.1186/1479-5876-10-104